We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), on Friday defended overriding the CDC’s own advisory panel, which voted the previous day not to recommend a Pfizer COVID-19 booster shot for people at high risk of contracting the disease in the workplace. Read More
Gilead Sciences’ antiviral drug Veklury (remdesivir) appeared to reduce hospitalizations and death by 87 percent in patients with new cases of COVID-19, according to data just released by the company. Read More
A Centers for Disease Control and Prevention (CDC) expert panel yesterday voted 9 to 6 that people aged 18-49 with underlying health conditions should be eligible to receive a booster vaccine, but voted down, 6 to 9, recommending a booster shot for people in that age group at risk of contracting the coronavirus based on their workplace. Read More
The FDA yesterday authorized booster shots of the Pfizer-BioNTech COVID-19 vaccine for people over 65 who have been vaccinated at least six months earlier with the two-dose shot. Read More
Johnson & Johnson (J&J) is poised to be the next company to jockey for approval for its COVID-19 vaccine booster, just days after FDA’s vaccine experts voted no on Pfizer-BioNTech’s booster for the general population. Read More
Pfizer-BioNTech’s COVID-19 vaccine for kids age five to 11 years appears ready for prime time as the first results from the companies’ trial of a COVID-19 vaccine in this age group are released. Read More
An FDA advisory panel declined Friday to recommend approval of a Pfizer/BioNTech COVID-19 vaccine booster for the general population but it voted unanimously, 18-0, to grant an updated Emergency Use Authorization (EUA) covering boosters in people 65 years and older as well as those at high-risk of progressing to severe disease. Read More